Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piroxicam-based sunscreen for early skin cancer lesions
ISRCTN22070974Phase 4Completed
- Sponsor
- Cantabria Labs
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of piroxicam in actinic keratosis (AK) and skin squamous cell carcinoma in situ (SCCIS), sponsored by Cantabria Labs. Primary endpoint: Clinical evolution of actinic keratosis lesion count in the target area. Started Sep 2016; status: completed.
02
Drugs
piroxicam
03
Conditions
actinic keratosis (AK)skin squamous cell carcinoma in situ (SCCIS)
Beyond the preview
Go deeper on ISRCTN22070974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN22070974.